Overall, in addition to strategies that specifically block gut homing mediating molecules, IL-23 represents together with TNF-alpha one of the few already therapeutically established biological targets in clinical management of IBD further strengthening the case for the central pathogenicity of IL-23R+ Th17 cells in the context of IBD. This evidence concerns the gene IL23A and inflammatory bowel disease.